Kyung Hae Jung

15.9k total citations · 4 hit papers
269 papers, 7.9k citations indexed

About

Kyung Hae Jung is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kyung Hae Jung has authored 269 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Oncology, 101 papers in Pulmonary and Respiratory Medicine and 77 papers in Cancer Research. Recurrent topics in Kyung Hae Jung's work include HER2/EGFR in Cancer Research (77 papers), Breast Cancer Treatment Studies (63 papers) and Cancer Treatment and Pharmacology (59 papers). Kyung Hae Jung is often cited by papers focused on HER2/EGFR in Cancer Research (77 papers), Breast Cancer Treatment Studies (63 papers) and Cancer Treatment and Pharmacology (59 papers). Kyung Hae Jung collaborates with scholars based in South Korea, United States and Switzerland. Kyung Hae Jung's co-authors include Hee Jin Chang, Dae Yong Kim, Seung‐Yong Jeong, Hyo Seong Choi, Seok‐Byung Lim, Yong Sang Hong, Dae Kyung Sohn, Jee Hyun Kim, Tae Hyun Kim and Sun Young Kim and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Kyung Hae Jung

254 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial

2010 739 citations Seung‐Yong Jeong, Hyo Seong Choi et al. The Lancet Oncology profile →
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

2020 718 citations Shigehira Saji, Kyung Hae Jung et al. profile →
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

2017 337 citations Sara A. Hurvitz, Kyung Hae Jung et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyung Hae Jung South Korea	41	5.8k	2.5k	1.9k	1.5k	1.1k	269	7.9k
Hemming Johansson Sweden	44	4.4k 0.8×	2.3k 0.9×	1.2k 0.6×	1.7k 1.1×	633 0.6×	186	7.6k
Franck Bonnetain France	51	6.5k 1.1×	4.6k 1.8×	4.2k 2.2×	1.4k 0.9×	817 0.7×	288	11.2k
Esther Bastiaannet Netherlands	45	4.5k 0.8×	1.6k 0.6×	1.6k 0.8×	1.8k 1.2×	392 0.4×	263	6.9k
Gabe S. Sonke Netherlands	42	4.2k 0.7×	2.0k 0.8×	1.7k 0.9×	2.3k 1.5×	522 0.5×	314	8.2k
Lee S. Schwartzberg United States	49	6.0k 1.0×	1.7k 0.7×	2.3k 1.2×	1.5k 1.0×	401 0.4×	422	10.2k
Gerrit‐Jan Liefers Netherlands	52	5.2k 0.9×	1.8k 0.7×	1.7k 0.9×	2.8k 1.9×	670 0.6×	243	9.0k
Jee Hyun Kim South Korea	43	5.2k 0.9×	1.8k 0.7×	2.9k 1.5×	1.4k 0.9×	727 0.7×	320	8.1k
James D. Brierley Canada	54	2.9k 0.5×	4.3k 1.7×	2.0k 1.0×	605 0.4×	1.7k 1.6×	194	11.3k
Mark Clemons Canada	37	3.3k 0.6×	1.1k 0.4×	1.3k 0.7×	1.0k 0.7×	899 0.8×	218	5.3k
Rajendra Badwe India	33	3.2k 0.6×	1.2k 0.5×	1.1k 0.6×	1.3k 0.9×	591 0.5×	183	5.6k

Countries citing papers authored by Kyung Hae Jung

Since Specialization

Citations

This map shows the geographic impact of Kyung Hae Jung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyung Hae Jung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyung Hae Jung more than expected).

Fields of papers citing papers by Kyung Hae Jung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyung Hae Jung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyung Hae Jung. The network helps show where Kyung Hae Jung may publish in the future.

Co-authorship network of co-authors of Kyung Hae Jung

This figure shows the co-authorship network connecting the top 25 collaborators of Kyung Hae Jung. A scholar is included among the top collaborators of Kyung Hae Jung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyung Hae Jung. Kyung Hae Jung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Soo Young, Hyehyun Jeong, Jin‐Hee Ahn, et al.. (2025). Ten-Year Follow-up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer. Cancer Research and Treatment. 58(1). 151–158.

Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2025). Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 42(5). 2015–2018. 2 indexed citations

Yun, Je‐Yeon, Bhumsuk Keam, Na‐Ri Lee, et al.. (2024). Depression, performance status, and discontinued treatment mediate an association of curability belief with prognosis in advanced cancer patients. Scientific Reports. 14(1). 29098–29098.

Park, Yeon Hee, Kyung-Hun Lee, Gun Min Kim, et al.. (2024). Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.. Journal of Clinical Oncology. 42(17_suppl). LBA1002–LBA1002. 1 indexed citations

Lee, Dae‐Won, Kyung Hae Jung, Kyung-Hun Lee, et al.. (2023). Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. European Journal of Cancer. 197. 113456–113456. 1 indexed citations

Dent, Rebecca, David W. Cescon, Thomas Bachelot, et al.. (2023). TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncology. 19(35). 2349–2359. 29 indexed citations

Dent, Rebecca, David W. Cescon, Thomas Bachelot, et al.. (2023). Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy. Cancer Research. 83(5_Supplement). OT1–3. 4 indexed citations

Lee, Soo Hyun, Kyunghee Park, Gun Min Kim, et al.. (2022). Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. The Breast. 62. 52–60. 17 indexed citations

Bardia, Aditya, Fei Su, Nadia Solovieff, et al.. (2021). Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precision Oncology. 5(5). 1408–1420. 24 indexed citations

10.

Jeong, Jae Ho, Jeong Eun Kim, Jin‐Hee Ahn, et al.. (2020). Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. European Journal of Cancer. 144. 341–350. 7 indexed citations

11.

Lee, Soo Hyun, Seock‐Ah Im, Gun Min Kim, et al.. (2020). Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers. 12(11). 3265–3265. 13 indexed citations

12.

Kim, Ji‐Yeon, Seri Park, Seock‐Ah Im, et al.. (2019). Quality of life outcomes including neuropathy‐associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line chemotherapy for HER2‐negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13‐11). Cancer Communications. 39(1). 29–29. 3 indexed citations

13.

Yun, Young Ho, Kyoung‐Nam Kim, Jin-Ah Sim, et al.. (2018). Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal of futile life-sustaining treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentred cross-sectional survey of Korean patients with cancer, their family caregivers, physicians and the general Korean population. BMJ Open. 8(9). e020519–e020519. 24 indexed citations

14.

Lee, Sae Byul, Guiyun Sohn, Jisun Kim, et al.. (2018). A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer. Cancer Research and Treatment. 51(3). 1073–1085. 25 indexed citations

15.

Seo, An Na, Hee Jin Lee, Eun Joo Kim, et al.. (2016). Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. British Journal of Cancer. 114(10). 1109–1116. 37 indexed citations

16.

Kim, Se Hyun, Kyung Hae Jung, Tae‐Yong Kim, et al.. (2016). Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. Cancer Research and Treatment. 48(4). 1373–1381. 8 indexed citations

17.

Hong, Yong Sang, Byung‐Ho Nam, Kyu-pyo Kim, et al.. (2014). Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. The Lancet Oncology. 15(11). 1245–1253. 265 indexed citations

18.

Yeo, Winnie, Kyung Hae Jung, Seock‐Ah Im, et al.. (2013). Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology. 31(14). 1732–1739. 54 indexed citations

19.

Kim, Kyu-pyo, Jin Hee Ahn, Sung‐Bae Kim, et al.. (2012). Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemotherapy and Pharmacology. 69(5). 1221–1227. 35 indexed citations

20.

Kim, Duck‐Woo, Duck‐Woo Kim, Dae Yong Kim, et al.. (2006). Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?. Cancer. 106(8). 1694–1700. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact